Clinical trials: Iron Overload
Beta-Thalassemia
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
This study is a Phase 2 multicenter, randomized, open-label, parallel-group study. The primary objective of the study is to evaluate the effect of LJPC-401 (synthetic human hepcidin) on iron levels in patients with…
- Trial name
- NCT03381833
- Testing
- LJPC-401
- Where
- 22 sites in United States, Australia and 6 more
- Volunteers
- 84 people
- Sponsor
- La Jolla Pharmaceutical Company
β-thalassemia, Transfusional Iron Overload
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
The primary purpose of this study is to evaluate the effect of deferasirox on renal hemodynamics by determining glomerular filtration rate (GFR), renal plasma flow (RPF) and filtration fraction (FF).
- Trial name
- NCT00560820
- Testing
- Deferasirox
- Where
- 3 sites in Italy
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Beta-Thalassemia, Iron Overload
Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients
This is a randomized, open label, two arms superiority trial of a representative population of patients with a primary diagnosis of transfusion dependent thalassemia with evidence of moderate cardiac iron overload, defined as an…
- Trial name
- CANALI (NCT02474420)
- Testing
- Amlodipine, Deferasirox
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Kevin H.M. Kuo, MD, MSc, FRCPC
Hereditary Haemochromatosis
Mi-iron - Moderately Increased Iron - is Reducing Iron Overload Necessary?
Haemochromatosis is a preventable genetic iron overload disorder. Untreated, it can shorten life due mainly to liver cirrhosis and cancer. It can be prevented by blood donation to maintain normal iron levels.
- Trial name
- Mi-iron (NCT01631708)
- Testing
- Erythrocytapheresis, Plasmapheresis
- Where
- 3 sites in Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Beta-thalassemia, Iron Overload
Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
The purpose of this trial is to evaluate changes in cardiac iron as measured by MRI T2* in beta-thalassemia patients with deferasirox treatment.
- Trial name
- NCT00447694
- Testing
- Deferasirox
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Novartis
Transfusional Iron Overload, Beta-thalassemia
Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload
The purpose of this research study is to evaluate the safety of two doses of FBS0701, a new oral iron chelator, and its effectiveness in clearing iron from the liver.
- Trial name
- NCT01186419
- Testing
- SPD602 (FBS0701, SSP-004184)
- Where
- 9 sites in United States, Italy and 3 more
- Volunteers
- 51 people
- Sponsor
- Shire
Hemochromatosis
Study of the Cellular Diffusion of Tacrolimus Across the Membrane of Mononuclear Cells
Pharmacokinetics of tacrolimus are highly variable and may result in graft rejection (underdosing) or toxicity (overdosing). The risk of transplant rejection and the toxicity of tacrolimus can be reduced by pharmacological…
- Trial name
- DIFF-TAC (NCT03654794)
- Testing
- Cell pharmacokinetics of tacrolimus
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Rennes University Hospital
Iron Overload
Safety and Efficacy of Iron Reduction by Phlebotomy
Hypothesis: The reduction of total body iron by phlebotomy will be safe and feasible in the post-HSCT setting Iron overload is common after hematopoietic stem cell transplantation.
- Trial name
- NCT00689182
- Testing
- monthly phlebotomy x 12 months
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- Andrea Kew
Genetic/Metabolic Liver Diseases
China Registry for Genetic / Metabolic Liver Diseases
CR-GMLD registry started on June 13, 2015 to collect cases of genetic/metabolic liver diseases from tertiary or secondary hospitals in mainland China.
- Trial name
- NCT03131427
- Testing
- Standard of care
- Where
- 12 sites in China
- Volunteers
- 20,000 people
- Sponsor
- Beijing Friendship Hospital
Iron Overload
The Iron Content of Ferritin in Serum and Urine of Children With High Serum Ferritin Levels
A serum ferritin level can reflect the total body iron content, thus a very low serum ferritin is commonly used as an indicator of iron deficiency and a very high serum ferritin is commonly used as a marker of iron overload.
- Trial name
- NCT03777904
- Testing
- Serum Ferritin level, Serum Ferritin iron content, Urine Ferritin level
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Utah
Iron Overload, Hemochromatosis
Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content
The purpose of this multi-site research is to validate a rapid magnetic resonance based confounder-corrected R-2 mapping method as a quantitative imaging biomarker of liver iron concentrations.
- Conditions
- Iron Overload, Hemochromatosis, Hemosiderosis
- Trial name
- NCT02025543
- Testing
- MRI
- Where
- 4 sites in United States
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Hereditary Hemochromatosis
PTG-300 in Subjects With Hereditary Hemochromatosis
This study will be conducted at multiple sites and every patient will get treated with PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult hereditary hemochromatosis patients.
- Trial name
- NCT04202965
- Testing
- PTG-300
- Where
- 11 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Protagonist Therapeutics, Inc.
Myelodysplastic Syndromes
Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
The scientific rationale for this study is the evolving understanding that iron-induced tissue damage is not only a process of progressive bulking of organs through high-volumes iron deposition, but also a reactive iron species…
- Trial name
- NCT03920657
- Testing
- Deferasirox
- Where
- 10 sites in Italy
- Volunteers
- 11 people
- Sponsor
- Fondazione Italiana Sindromi Mielodisplastiche-ETS
Iron Overload
Safety of SP-420 in the Treatment of Transfusional Iron Overload
This study enrolls patients with myelodysplastic syndrome (MDS) and myelofibrosis (MFS), with transfusional iron overload and treats them with the investigational iron chelator, SP-420.
- Trial name
- NCT04741542
- Testing
- SP-420
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Iron Overload
Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients
The primary objective is to assess the safety of Ferriprox oral solution for the treatment of iron overload in pediatric patients with transfusion-dependent anemia.
- Trial name
- NCT00529152
- Testing
- Deferiprone
- Where
- 4 sites in Egypt, Indonesia and 1 more
- Volunteers
- 100 people
- Sponsor
- ApoPharma
Iron Overload
Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload
The purpose of this study is to investigate the effects of iron chelation using deferasirox in patients who show signs of iron overload after an allogeneic stem cell transplantation The iron overload must be due to blood…
- Trial name
- NCT00654589
- Testing
- Deferasirox
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Novartis Pharmaceuticals
Beta Thalassemia Major
Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia
the aim of this study is to evaluate the effect of Spirulina compared to Amlodipine on cardiac iron overload and cardiac functions in multi-transfused children with beta thalassemia major
- Trial name
- NCT02671695
- Testing
- Spirulina, Amlodipine
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Tanta University
Liver Cirrhosis, Iron Overload
Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only in Patients With Dysmetabolic Liversiderosis
Insulin resistance-associated hepatic iron overload (IR-HIO), also defined as dysmetabolic iron overload syndrome or dysmetabolic liversiderosis, is a common cause or iron overload in France, mainly in middle-age patients with…
- Trial name
- SAIGNEES (NCT01045525)
- Testing
- Phlebotomy, Lifestyle and diet advices
- Where
- 5 sites in France
- Volunteers
- 274 people
- Sponsor
- Rennes University Hospital
Thalassemia, Sickle Cell Disease
Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations
The investigators' primary objective is to study prevalences of myocardial iron overload, defined as a cardiac T2*< 20 ms, in 3 populations of multiply transfused patients, affected with thalassemia, sickle cell disease, and…
- Conditions
- Thalassemia, Sickle Cell Disease, Myelodysplasia
- Trial name
- SUFEMYO (NCT01911871)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Transfusional Hemosiderosis
Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox
This study will observe patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.
- Trial name
- NCT01394029
- Testing
- deferasirox
- Where
- 10 sites in Egypt, Jordan and 2 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals